Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Commercial and Pipeline Insight - Allergic Rhinitis (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 08 Oct 2007
- Report Title: Commercial and Pipeline Insight - Allergic Rhinitis
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 319
Introduction
The allergic rhinitis market will continue to decline over the next few years, after which it will resume limited growth due to the introduction of new compounds and combination products. These will drive the expansion of sales in existing classes as they exhibit safety and convenience advantages. Meanwhile, immunotherapy is expected to move from its niche position into mainstream therapy.
Scope
Indication-based forecasts for allergic rhinitis products and significant pipeline drugs Assessment of country-specific drivers and resistors likely to impact the market Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates Assessment of the remaining unmet clinical needs in allergic rhinitis, analyzing the potential of new targeted therapies
Highlights
The allergic rhinitis market was worth about $10 billion in 2006 and has been decreasing in value over the last few years due to patent expiries and limited levels of innovation. The top 2 drug classes prescribed for the treatment of allergic rhinitisoral antihistamines and nasal corticosteroidsaccounted for 77% of the total sales in this market. At least 3 major allergic rhinitis players have developed and launched an oral antihistamine/decongestant fixed dose combination. However, several practical concerns have limited the use of these treatments and none of the products have reached sales as high as their single antihistamine component. The immunotherapy market is moving from a niche position towards baseline therapy. The report expects a sublingual tablet for the treatment of grass allergy (such as Grazax) to be able to reach annual sales of $780m to $1.3 billion, depending on the patient population targeted, the length of administration and price of the product.
Reasons to Purchase
Identify key opportunities and threats that will impact the use and uptake of new and existing products Quantify the future size and scope of the allergic rhinitis market and predict the future performance of key compounds Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development
The allergic rhinitis market will continue to decline over the next few years, after which it will resume limited growth due to the introduction of new compounds and combination products. These will drive the expansion of sales in existing classes as they exhibit safety and convenience advantages. Meanwhile, immunotherapy is expected to move from its niche position into mainstream therapy.
Scope
Indication-based forecasts for allergic rhinitis products and significant pipeline drugs Assessment of country-specific drivers and resistors likely to impact the market Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates Assessment of the remaining unmet clinical needs in allergic rhinitis, analyzing the potential of new targeted therapies
Highlights
The allergic rhinitis market was worth about $10 billion in 2006 and has been decreasing in value over the last few years due to patent expiries and limited levels of innovation. The top 2 drug classes prescribed for the treatment of allergic rhinitisoral antihistamines and nasal corticosteroidsaccounted for 77% of the total sales in this market. At least 3 major allergic rhinitis players have developed and launched an oral antihistamine/decongestant fixed dose combination. However, several practical concerns have limited the use of these treatments and none of the products have reached sales as high as their single antihistamine component. The immunotherapy market is moving from a niche position towards baseline therapy. The report expects a sublingual tablet for the treatment of grass allergy (such as Grazax) to be able to reach annual sales of $780m to $1.3 billion, depending on the patient population targeted, the length of administration and price of the product.
Reasons to Purchase
Identify key opportunities and threats that will impact the use and uptake of new and existing products Quantify the future size and scope of the allergic rhinitis market and predict the future performance of key compounds Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development
Browse over 450,000 market research reports, company profile reports and company financials. Search by industry sector, or simply search market research reports or company profiles by keyword. Companiesandmarkets.com contains one of the world's largest collections of market research reports and company profiles from leading global market research report publishers and analysts. Global brands rely on companiesandmarkets.com for their strategic market research needs.
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card, Credit Card, or by Invoice.
Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
